Résultats de la recherche
10
Tout
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
26 févr. 2025 07h00 HE
|
Immunocore Holdings plc
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials...
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
19 févr. 2025 07h00 HE
|
Immunocore Holdings plc
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology...
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
10 janv. 2025 07h00 HE
|
Immunocore Holdings plc
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma...
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 07h00 HE
|
Immunocore Holdings plc
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc...
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
02 janv. 2025 07h00 HE
|
Immunocore Holdings plc
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
23 déc. 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets...
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
17 déc. 2024 07h00 HE
|
Immunocore Holdings plc
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First...
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11 déc. 2024 07h00 HE
|
Immunocore Holdings plc
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
03 déc. 2024 01h00 HE
|
Immunocore Holdings plc
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England &...
Immunocore to present at upcoming investor conferences
08 nov. 2024 07h00 HE
|
Immunocore Holdings plc
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology...